Glia cells contribute to motor neuron degeneration and aggravate the progression of amyotrophic lateral sclerosis (ALS), an idiopathic, fatal neurodegenerative disease of the human motor system. The nature of this contribution is not yet fully defined. Deficient expression and activity of the astroglia glutamate transporter EAAT2 (a.k.a. GLT-1 in rodents) has been reported in ALS and the excitotoxicity resulting from the ensuing accumulation of glutamate is one conventional mechanism that could contribute to motor neuron degeneration. We unraveled an unconventional way for EAAT2 to trigger motor neuron toxicity. We showed that caspase-3 selectively cleaves EAAT2 in ALS, presumably through a mechanism that involves restricted non-apoptotic caspase-3 activation in astrocytes, generating a cytosolic EAAT2 C-terminus SUMOylated fragment (CTE- SUMO1). This fragment, when exogenously expressed in astrocytes, accumulates in their nuclei in PML- nuclear bodies and indirectly causes motor neuron toxicity via a mechanism that involves increased expression and release of netrin-1. Oligodendrocytes, not astrocytes, secrete netrin-1 in the normal adult CNS to maintain axonal homeostasis. Hence, an abnormal non-physiological release of netrin-1 from CTE-SUMO1+ astrocytes could be one non-cell autonomous mechanism of toxicity to motor neurons in vivo as well. We propose in this application to expand the relevance of our in vitro findings by testing in vivo the hypothesis of whether CTE-SUMO1 is responsible for motor neuron impairment and ALS-like phenotype. To restate our goal in terms of specific aims, we propose: (1) To determine whether CTE-SUMO1 is a mediator of motor neuron impairment in vivo and assess the modalities of toxicity;(2) To determine whether preventing the accumulation of CTE-SUMO1 subsides the ALS phenotype.
Aim 1 involves selective expression of CTE-SUMO1in ventral horn astrocytes of adult mice to evaluate its possible toxic effects on the entire phrenic motor neuron pool targeted via intraspinal focal injections of an AAV1-CTE-SUMO1 viral construct at the C4-C6 cervical level.
Aim 2 involves the creation of a novel knock-in SOD1-G93A mouse model in which the caspase-3 cleavage site in EAAT2 is mutated to prevent the endogenous production of CTE-SUMO1. In addition to these in vivo experiments, we propose: (3) To determine the disease-relevant effectors responsible for CTE-SUMO1 accumulation in astrocytes. We expect to unravel the modalities of CTE-SUMO1 generation in astrocytes and whether the presence of familial ALS-linked causative mutations catalyzes the process. It is a matter of importance to understand what effectors could lead to the cleavage of EAAT2 and therefore the ensuing CTE-SUMO1 creation. This knowledge can then be applied to design pharmacological approaches aiming at arresting CTE-SUMO1 production in ALS. The scope of this last aim could then be key, in particular if results of aim 1-2 establisha role of the astroglial CTE-SUMO1 fragment in motor neuron toxicity and ALS pathogenesis.

Public Health Relevance

Amyotrophic lateral sclerosis (ALS) is one of the most devastating and lethal progressive neuromuscular disorders, which causes the degeneration of motor neurons in the spinal cord and motor cortex. Over 30,000 people are living with this disease in the United States and approximately 5,000 Americans will be diagnosed with ALS this year. We have uncovered a novel mechanism in which non-neuronal cells take part to the degeneration of motor neurons in ALS via a peptidic fragment of the glutamate transporter EAAT2. The contribution of this mechanism to the disease phenotype will be validated in this application using animal model of the disease. Our ultimate goal is to understand the pathogenic mechanisms of ALS to improve our chances of a successful therapeutic approach for this disease. !

National Institute of Health (NIH)
Research Project (R01)
Project #
Application #
Study Section
Cell Death and Injury in Neurodegeneration Study Section (CDIN)
Program Officer
Gubitz, Amelie
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Thomas Jefferson University
Schools of Medicine
United States
Zip Code
Foran, E; Rosenblum, L; Bogush, A et al. (2014) Sumoylation of the astroglial glutamate transporter EAAT2 governs its intracellular compartmentalization. Glia 62:1241-53
Tan, Wenzhi; Pasinelli, Piera; Trotti, Davide (2014) Role of mitochondria in mutant SOD1 linked amyotrophic lateral sclerosis. Biochim Biophys Acta 1842:1295-301
Foran, Emily; Rosenblum, Lauren; Bogush, Alexey I et al. (2013) Sumoylation of critical proteins in amyotrophic lateral sclerosis: emerging pathways of pathogenesis. Neuromolecular Med 15:760-70
Jablonski, Michael R; Jacob, Dena A; Campos, Christopher et al. (2012) Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS. Neurobiol Dis 47:194-200
Foran, Emily; Bogush, Alexey; Goffredo, Michael et al. (2011) Motor neuron impairment mediated by a sumoylated fragment of the glial glutamate transporter EAAT2. Glia 59:1719-31
Boston-Howes, William; Williams, Eric O; Bogush, Alexey et al. (2008) Nordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: therapeutic implications for amyotrophic lateral sclerosis. Exp Neurol 213:229-37
Gibb, Stuart L; Boston-Howes, William; Lavina, Zeno S et al. (2007) A caspase-3-cleaved fragment of the glial glutamate transporter EAAT2 is sumoylated and targeted to promyelocytic leukemia nuclear bodies in mutant SOD1-linked amyotrophic lateral sclerosis. J Biol Chem 282:32480-90
Boston-Howes, William; Gibb, Stuart L; Williams, Eric O et al. (2006) Caspase-3 cleaves and inactivates the glutamate transporter EAAT2. J Biol Chem 281:14076-84
Pasinelli, Piera; Belford, Mary Elizabeth; Lennon, Niall et al. (2004) Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 43:19-30